Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) major shareholder Morningside Venture Investment sold 50,000 shares of the firm's stock in a transaction on Wednesday, January 25th. The stock was sold at an average price of $6.85, for a total value of $342,500.00. Following the transaction, the insider now owns 5,662,993 shares in the company, valued at $38,791,502.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Morningside Venture Investment also recently made the following trade(s):

• On Monday, January 23rd, Morningside Venture Investment sold 80,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.81, for a total value of $544,800.00.
• On Tuesday, January 17th, Morningside Venture Investment sold 6,114 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.79, for a total value of $41,514.06.
• On Thursday, January 12th, Morningside Venture Investment sold 5,000 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.77, for a total value of $33,850.00.
• On Thursday, January 5th, Morningside Venture Investment sold 12,162 shares of Kezar Life Sciences stock. The stock was sold at an average price of $6.97, for a total value of $84,769.14.

Kezar Life Sciences Stock Performance

KZR stock opened at $6.90 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 31.15 and a current ratio of 31.15. The stock has a market capitalization of $471.82 million, a price-to-earnings ratio of -6.83 and a beta of 0.23. Kezar Life Sciences, Inc. has a 1 year low of $4.30 and a 1 year high of $18.55. The stock's fifty day moving average is $6.98 and its two-hundred day moving average is $8.24.

Institutional Investors Weigh In On Kezar Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Great West Life Assurance Co. Can bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $26,000. Tower Research Capital LLC TRC raised its stake in shares of Kezar Life Sciences by 88.9% during the third quarter. Tower Research Capital LLC TRC now owns 6,777 shares of the company's stock valued at $58,000 after purchasing an additional 3,190 shares in the last quarter. Robeco Institutional Asset Management B.V. bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $68,000. Amalgamated Bank bought a new stake in shares of Kezar Life Sciences during the first quarter valued at about $70,000. Finally, UBS Asset Management Americas Inc. bought a new stake in shares of Kezar Life Sciences during the third quarter valued at about $86,000. 84.03% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company cut their target price on Kezar Life Sciences from $17.00 to $14.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 3rd.

Kezar Life Sciences Company Profile

(Get Rating)

Kezar Life Sciences, Inc is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco and California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J.

Featured Stories

• Get a free copy of the StockNews.com research report on Kezar Life Sciences (KZR)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.